ReviewClinical & experimental metastasis2009
Prediction of breast cancer metastasis by genomic profiling: where do we stand?
Review in Clinical & experimental metastasis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?Clinical & experimental metastasis · 2010Pooled it
- Machine Learning Methods for Gene Selection in Uveal Melanoma.International journal of molecular sciences · 2024Article
- Construction and validation of a 6-gene nomogram discriminating lung metastasis risk of breast cancer patients.PloS one · 2020Article
- Data Fusion Techniques for the Integration of Multi-Domain Genomic Data from Uveal Melanoma.Cancers · 2019Article
- Relevance of MicroRNAs as Potential Diagnostic and Prognostic Markers in Colorectal Cancer.International journal of molecular sciences · 2018Review
- The biology of uveal melanoma.Cancer metastasis reviews · 2017Review
- Article
- MicroRNAs in colorectal cancer: role in metastasis and clinical perspectives.World journal of gastroenterology · 2014Review
- Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.Cancer metastasis reviews · 2014Review
- Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.PloS one · 2014Article
- Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.Breast cancer research and treatment · 2013Article
- The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis.Journal of cellular physiology · 2013Review
- Micro-RNA-632 downregulates DNAJB6 in breast cancer.Laboratory investigation; a journal of technical methods and pathology · 2012Article
- AACR centennial series: the biology of cancer metastasis: historical perspective.Cancer research · 2010Review
- Survival Online: a web-based service for the analysis of correlations between gene expression and clinical and follow-up data.BMC bioinformatics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current concepts conceive "breast cancer" as a complex disease that comprises several very different types of neoplasms. Nonetheless, breast cancer treatment has considerably improved through early diagnosis, adjuvant chemotherapy, and endocrine treatments. The limited prognostic power of classical classifiers determines considerable over-treatment of women who either do not benefit from, or do not at all need, chemotherapy. Several gene expression based molecular classifiers (signatures) have been developed for a more reliable prognostication. Gene expression profiling identifies profound differences in breast cancers, most probably as a consequence of different cellular origin and different driving mutations and can therefore distinguish the intrinsic propensity to metastasize. Existing signatures have been shown to be useful for treatment decisions, although they have been developed using relatively small sample numbers. Major improvements are expected from the use of large datasets, subtype specific signatures and from the re-introduction of functional information. We show that molecular signatures encounter clear limitations given by the intrinsic probabilistic nature of breast cancer metastasis. Already today, signatures are, however, useful for clinical decisions in specific cases, in particular if the personal inclination of the patient towards different treatment strategies is taken into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.